New agents in the therapy of hormone-refractory patients with prostate cancer.
Kantoff
P W
PW
Department of Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02115-6084.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011788:Quality of Life; D013498:Suramin / Q000008:administration & dosage; D016019:Survival Analysis
D013498:Suramin; D008942:Mitoxantrone; D017430:Prostate-Specific Antigen